Wells Fargo & Company Larimar Therapeutics, Inc. Call Options Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LRMR
# of Institutions
128Shares Held
67.3MCall Options Held
280KPut Options Held
76.3K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$84.1 Million2.59% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$23.9 Million0.55% of portfolio
-
Janus Henderson Group PLC London, X05.57MShares$22 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.25MShares$16.8 Million0.0% of portfolio
-
Blue Owl Capital Holdings LP New York, NY4.17MShares$16.5 Million9.0% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $171M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...